XBI ETF Analysis: S&P Biotech | NYSE
Health | NYSE, USA | Market Cap: 10.393m USD | 12M Return: 63.3% | US78464A8707 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.27B
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that seeks to track the performance of the S&P Biotechnology Select Industry Index, which represents the biotechnology segment of the broader S&P Total Market Index. To achieve its objective, the fund uses a sampling strategy, investing at least 80% of its total assets in securities that make up the underlying index. Launched in January 2006, XBI provides investors with targeted exposure to U.S. mid-cap biotechnology companies.
Biotechnology companies typically focus on developing therapies, diagnostics, and vaccines derived from biological processes, often serving healthcare markets such as oncology, rare diseases, and infectious diseases. Sector-specific ETFs like XBI offer investors a diversified way to gain exposure to this industry without selecting individual stocks, though the sector is generally known for higher volatility due to its reliance on clinical trial outcomes, regulatory approvals, and patent cycles.
- FDA approval pipeline accelerates biotech rally
- Fed rate cuts support biotech valuations
- Pharma M&A activity boosts acquisition premiums
As of September 22, 2026, the stock is trading at USD 158.23 with a total of 7,846,623 shares traded. Over the past week, the price has changed by +0.40%, over one month by -4.53%, over three months by +8.48% and over the past year by +63.31%.
Current recommended Stop Loss: 148.60 (which is 6.1% or 2.4 ATR below the current price).
S&P Biotech has no consensus analysts rating.